{"id":79337,"date":"2026-05-10T21:18:15","date_gmt":"2026-05-10T21:18:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/79337\/"},"modified":"2026-05-10T21:18:15","modified_gmt":"2026-05-10T21:18:15","slug":"lexicon-lxrx-reports-21-1m-q1-revenue-driven-by-novo-nordisk-milestones-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/79337\/","title":{"rendered":"Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones"},"content":{"rendered":"\n

\u200bLexicon Pharmaceuticals Inc. (NASDAQ:LXRX<\/a>) is one of the best fast growing penny stocks to buy right now<\/a>. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior year, driven by $20.0 million in development milestones from its LX9851 partnership with Novo Nordisk. The company achieved a sharp reduction in net loss to $1.0 million, compared to $25.3 million in Q1 2025, benefiting from lower research and marketing expenses.<\/p>\n

Lexicon ended the quarter with a strengthened balance sheet featuring $199.7 million in cash and investments, further supported by a new $100 million loan facility from Hercules Capital. On the clinical front, the company is progressing toward several major milestones, including the anticipated mid-2026 completion of enrollment for its Phase 3 SONATA-HCM study of sotagliflozin. The company also expects to resubmit its NDA for ZYNQUISTA in type 1 diabetes by mid-2026, with potential regulatory approval later this year.<\/p>\n

\"Is Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? <\/p>\n

Additionally, partner Novo Nordisk has initiated Phase 1 clinical development of LX9851 for obesity, a milestone that earned Lexicon $10 million in March with the potential for another payment later in 2026. Beyond its cardiometabolic pipeline, \u200bLexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is preparing for Phase 3 development of pilavapadin (LX9211) for diabetic peripheral neuropathic pain after the FDA raised no objections to its proposed registrational study design.<\/p>\n

\u200bLexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat human disease.<\/p>\n

While we acknowledge the potential of LXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy<\/a>.\u00a0<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"\u200bLexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On…\n","protected":false},"author":2,"featured_media":79338,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[26614,42280,26431,272],"class_list":["post-79337","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-clinical-development","tag-development-milestones","tag-lexicon-pharmaceuticals","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116552368583916156","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/79337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=79337"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/79337\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/79338"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=79337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=79337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=79337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}